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Introduction
The  mammalian  target  of  rapamycin  (mTOR)  is  a  Ser/Thr   
kinase critically involved in the regulation of many cellular and 
developmental processes including cell growth, differentiation, 
and metabolism. Two functionally distinct protein complexes 
containing mTOR have been characterized, namely mTORC1 
and  mTORC2,  which  mediate  the  rapamycin-sensitive  and   
-insensitive signaling of mTOR, respectively (Sarbassov et al., 
2005a). mTORC1 assembles a signaling network in the regula-
tion of cell growth by mediating nutrient availability (amino acid   
sufficiency)  and  mitogenic  signals.  The  two  best-characterized   
immediate targets of mTORC1 are ribosomal S6 kinase 1 
(S6K1) and eukaryotic initiation factor–4E-binding protein 1 
(4E-BP1), both of which regulate protein synthesis at the trans-
lation initiation level (Hay and Sonenberg, 2004). The tumor 
suppressor tuberous sclerosis complex TSC1–TSC2 and the tar-
get of its GTPase-activating protein activity, Rheb, form a major 
hub that receives multiple upstream signals to activate mTORC1 
(Manning and Cantley, 2003).
The sensing and transduction of amino acid signals up-
stream of mTORC1 have been an issue of long-standing interest, 
as this mechanistically less well-understood aspect of mTOR 
regulation represents a fundamentally important signaling pro-
cess and may be intimately linked to human diseases such as 
cancer and metabolic syndromes. To date, two major pathways 
have been reported to mediate amino acid signals to activate 
mTORC1, involving the class III phosphatidylinositol 3-kinase 
(PI-3-kinase) human vacuolar protein sorting 34 (hVps34) and 
the Rag family of small G proteins. hVps34 has been found to 
be activated by amino acids and required for mTORC1 activa-
tion in response to amino acid stimulation (Byfield et al., 2005; 
Nobukuni et al., 2005). In vivo validation of hVps34 as a key 
regulator of mTORC1 came from a recent study showing that 
hVps34-deficient embryos had drastically reduced levels of S6 
phosphorylation and were defective in cell proliferation (Zhou 
et al., 2011). As upstream regulators, calcium and CaM have 
been shown to bind and activate hVps34 (Gulati et al., 2008), 
T
he rapamycin-sensitive mammalian target of rapa-
mycin (mTOR) complex, mTORC1, regulates cell 
growth  in  response  to  mitogenic  signals  and 
amino acid availability. Phospholipase D (PLD) and its 
product,  phosphatidic  acid,  have  been  established  as   
mediators  of  mitogenic  activation  of  mTORC1.  In  this 
study, we identify a novel role for PLD1 in an amino acid–
sensing pathway. We find that amino acids activate PLD1 
and that PLD1 is indispensable for amino acid activation   
of mTORC1. Activation of PLD1 by amino acids requires 
the class III phosphatidylinositol 3-kinase hVps34, which 
stimulates PLD1 activity through a functional interaction 
between phosphatidylinositol 3-phosphate and the Phox 
homology (PX) domain of PLD1. Furthermore, amino acids   
stimulate PLD1 translocation to the lysosomal region where 
mTORC1  activation  occurs  in  an  hVps34-dependent 
manner, and this translocation is necessary for mTORC1   
activation. The PX domain is required for PLD1 transloca-
tion, mTORC1 activation, and cell size regulation. Finally, 
we show that the hVps34-PLD1 pathway acts indepen-
dently of, and in parallel to, the Rag pathway in regulat-
ing amino acid activation of mTORC1.
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measured in vivo activities of recombinant proteins. As shown 
in Fig. 1 C, PLD1 was stimulated by amino acids, whereas 
PLD2 displayed a higher unstimulated activity that was not   
affected significantly by amino acids (Fig. 1 C). Thus, PLD1 
appears to be the amino acid–sensitive isoform.
To examine a potential role of PLD1 in the amino acid–
sensing mTORC1 pathway, we knocked down PLD1 by lentivirus- 
mediated  expression  of  small  hairpin  RNA  (shRNA)  and 
found amino acid–induced S6K1 phosphorylation at Thr389 and 
4E-BP1 phosphorylation at Thr37/46, both common readouts 
for mTORC1 activity, to be significantly decreased (Fig. 1 D). 
The effect was observed with two independent shRNAs, validat-
ing the specificity of the RNAi. Leu-stimulated phosphorylation 
of S6K1 and 4E-BP1 was also inhibited by PLD1 knockdown 
(Fig. 1 E). Knockdown of PLD1 blocked amino acid activation 
of S6K1 in four other cell lines as well (Fig. 1 F). Knockdown of 
PLD2, on the other hand, did not have any effect on amino acid 
stimulation (Fig. S1), which is consistent with the lack of PLD2 
activation by amino acids (Fig. 1 C). It should be noted that   
endogenous PLD2 activity in HEK293 cells is very low, and the 
protein is difficult to detect (Slaaby et al., 2000), so that PLD1 is 
likely the major contributor to the total cellular PLD activity in 
these cells. So far, our results placed PLD1 downstream of amino 
acid signals that activate mTORC1.
hVps34 is necessary for amino acid 
activation of PLD1 upstream of mTORC1
In searching for a mechanism by which PLD1 might be acti-
vated by amino acid signals upstream of mTORC1, we consid-
ered one of the reported regulators in this pathway, hVps34 
(Byfield et al., 2005; Nobukuni et al., 2005). Amino acid activa-
tion of hVps34 leads to increased production of PI3P, and PI3P 
is known to regulate its effector proteins by binding to their 
Fab1/YOTB/Vac1/EEA1 (FYVE) or Phox homology (PX) do-
mains (Lemmon, 2003; Backer, 2008). As PLD1 contains a PX 
domain, we wondered whether hVps34 could be linked to PLD1 
through a PI3P–PX interaction. To probe this possibility, we 
first examined whether hVps34 lied upstream of PLD1 in the 
mTORC1 pathway. 3-methyladenine (3-MA), an hVps34 inhibi-
tor (Miller et al., 2010), blocked amino acid–stimulated cellular 
PLD activity, whereas rapamycin had no effect (Fig. 2 A). 
Wortmannin, another PI-3-kinase inhibitor, had a similar effect 
on PLD as 3-MA (unpublished data). At the same time, S6K1 
phosphorylation was abolished by 3-MA as well as by rapa-
mycin, as expected. As neither 3-MA nor any other known inhibi-
tor is absolutely specific for hVps34, we sought definitive 
evidence for hVps34 involvement by knockdown, which indeed 
inhibited amino acid activation of cellular PLD (Fig. 2 B). Insu-
lin stimulation of cellular PLD was also blocked by hVps34 
knockdown (Fig. 2 C), consistent with the notion that mitogenic 
stimulation of PLD is dependent on amino acid sufficiency. 
hVps34 knockdown inhibited amino acid– and insulin-stimulated 
S6K1  phosphorylation  (Fig.  2,  B  and  C)  but  not  insulin- 
stimulated Akt phosphorylation (Fig. 2 C), confirming the 
previously reported critical role of hVps34 in mTORC1 signal-
ing (Byfield et al., 2005; Nobukuni et al., 2005). Collectively, 
our  results  strongly  suggest  that  PLD  lies  downstream  of 
but others have questioned this mode of hVps34 regulation 
(Yan et al., 2009). Curiously, Vps34 does not regulate TOR 
signaling in Drosophila melanogaster (Juhasz et al., 2008), 
suggesting that the hVps34-mTOR regulatory branch may 
have evolved to accommodate the biological complexity in 
higher organisms. The Rag GTPase heterodimers, through the 
P18–P14–MP1 complex, recruit mTORC1 to the lysosomal sur-
face upon amino acid stimulation, where Rheb presumably re-
sides and mTORC1 activation occurs (Kim et al., 2008; Sancak 
et al., 2008, 2010). The Ste20 kinase MAP4K3 and its inhibitor 
PP2A/PR61- have also been reported to mediate amino acid 
signaling to mTORC1 in a Rag-dependent manner, although 
they may constitute a pathway parallel to Rag (Findlay et al., 
2007; Yan et al., 2010). It is not known how the hVps34 and Rag 
pathways are connected or how hVps34 activates mTORC1.
Mitogenic activation of mTORC1 also requires the lipid 
second messenger phosphatidic acid (PA), which binds to the 
FKBP12-rapamycin–binding domain of mTOR (Fang et al., 
2001; Foster, 2007; Sun and Chen, 2008). Phospholipase D 
(PLD),  catalyzing  the  hydrolysis  of  phosphatidylcholine  to 
PA, has been established as a key upstream component in the 
mitogenic mTORC1 pathway that regulates cell growth (Fang 
et al., 2003; Sun and Chen, 2008). Like hVps34, PLD does not 
regulate TOR in Drosophila (Sun and Chen, 2008). Of the two 
mammalian isoforms of PLD, PLD2 displays a high basal activ-
ity in most mammalian cells, whereas PLD1 has little activity in 
resting cells and is activated by a variety of mitogens and ago-
nists (Frohman et al., 1999). PLD1 has been found to be a Rheb 
effector, which directly connects the PA and tuberous sclerosis 
complex–Rheb  pathways  upstream  of  mTORC1  (Sun  et  al., 
2008). Here, we report a novel role of PLD1 in transducing 
amino acid signals to activate mTORC1 via an hVps34– phos-
phatidylinositol 3-phosphate (PI3P)–PLD1 pathway.
Results
PLD1 lies in an amino acid–sensing 
mTORC1 pathway
The PLD/PA axis had long been considered a mitogenic path-
way that acted in parallel to amino acid–sensing pathways up-
stream of mTORC1 (Fang et al., 2001, 2003); PLD had not 
been directly connected to amino acid signals. However, our re-
cent observation that serum stimulation of PLD activation was 
dependent on the presence of amino acids (Sun et al., 2008) 
prompted us to reexamine the relationship between PLD and 
amino acids. As shown in Fig. 1 A, amino acid withdrawal di-
minished basal cellular PLD activity in serum-starved HEK293 
cells. Furthermore, in serum-starved and amino acid–deprived 
cells, amino acids at the concentrations found in DME acutely 
stimulated PLD activity by 1.5-fold (Fig. 1 A), and this activation 
was also observed to various degrees in four other mouse and 
human cell lines (C2C12, HepG2, HeLa, and 3T3L1; Fig. 1 B). It 
is important to note that this seemingly modest degree of activa-
tion by amino acids is comparable with those induced by other 
well-known PLD stimuli such as insulin (Fig. 1 A; Voss et al., 
1999) and serum (Kötter et al., 2000; Sun et al., 2008). To dis-
tinguish  between  the  two  mammalian  isoforms  of  PLD,  we 437 PLD mediates amino acid activation of mTORC1 • Yoon et al.
It is noteworthy that exogenous PA could activate mTORC1 
signaling in the absence of mitogens (Fig. 2 E; Fang et al., 
2001) but not in the absence of amino acids (Fig. 2 F, first 
through fourth lanes). In other words, PA is sufficient to act as 
a  mitogen  in  the  mTORC1  pathway,  but  it  cannot  replace 
amino acid signals, suggesting that other amino acid–sensing 
pathways—for instance, the Rag pathway (Sancak et al., 2008, 
2010)—may be required in parallel with the PLD-PA pathway 
to transduce amino acid signals to mTORC1.
hVps34 activates PLD1 through PI3P
Further probing the relationship between hVps34 and PLD1, 
we overexpressed hVps34/hVps15 and examined the effect on 
PLD1 activity. hVps34 overexpression in HEK293 cells stimu-
lated PLD1 activity in a dose-dependent manner accompanied 
by increased S6K1 phosphorylation, as expected (Fig. 3 A). 
hVps34  overexpression  also  augmented  amino  acid–induced 
PLD1  activity  (Fig.  3  B).  These  results  are  consistent  with 
hVps34 being an activator of PLD1 in an amino acid–sensing 
pathway. To assess whether the kinase activity of hVps34 was 
required for PLD1 activation, we knocked down endogenous 
hVps34 and that amino acid activation of PLD requires the 
presence of hVps34.
Next, we asked whether PLD played a role in connecting 
hVps34  to  mTORC1  in  the  amino  acid–sensing  pathway. 
Overexpression of recombinant hVps34 enhanced the amino 
acid–induced activation of S6K1 (Fig. 2 D), as previously re-
ported  (Nobukuni  et  al.,  2005).  In  these  experiments,  we 
overexpressed  hVps34  and  hVps15  bicistronically  because 
coexpression of hVps15 resulted in higher specific activity of 
the  recombinant  hVps34  (Yan  et  al.,  2009).  The  hVps34- 
induced S6K1 phosphorylation was abolished by PLD1 knock-
down (Fig. 2 D), suggesting that PLD1 is necessary for hVps34 
activation of mTORC1. Although hVps34 knockdown sup-
pressed insulin- and amino acid–induced S6K1 phosphoryla-
tion (Fig. 2, B and C), it did not affect the activation of S6K1 
by exogenous PA (Fig. 2 E), which is consistent with PLD   
lying downstream of hVps34 and upstream of mTORC1. Fur-
thermore, exogenous PA rescued amino acid–induced S6K1 
phosphorylation from hVps34 knockdown (Fig. 2 F, last four 
lanes).  Collectively,  these  observations  put  PLD1  between 
hVps34 and mTORC1 in a pathway regulated by amino acids. 
Figure 1.  PLD1 is activated by amino acids in the mTORC1 pathway. (A) HEK293 cells were serum starved overnight followed by the following treatments: 
deprivation of amino acids (AA) for 2 h, restimulation with amino acids for 30 min, or stimulation with 100 nM insulin for 30 min. In vivo PLD assays were 
performed to measure total cellular PLD activity. (B) Various types of cells as indicated were serum starved overnight followed by amino acid withdrawal for 
2 h and then stimulated with amino acids for 30 min. Total cellular PLD activity was measured. (C) Recombinant PLD1 or PLD2 was transiently expressed, 
and the cells were treated as in B. Recombinant PLD activities were measured as described in Materials and methods. (A–C) All data are mean ± SD or 
representative blots from three to five independent experiments. A one-sample t test was performed to compare each sample with the control. *, P < 0.05; 
**, P < 0.01. (D) Cells were transduced with lentiviruses expressing two independent shRNAs against PLD1 and a scrambled (scram) sequence as a 
negative control, selected with puromycin, serum starved overnight, and amino acid deprived for 2 h followed by amino acid stimulation for 30 min. Cell 
lysates were analyzed by Western blotting. (E) Cells were treated as in D, except that Leu deprivation and stimulation were performed in lieu of amino 
acid deprivation/stimulation. (F) Four types of cells were treated as in D and analyzed by Western blotting. (D–F) All experiments were performed at least 
three times, and representative blots are shown. Predicted molecular masses of the proteins are indicated for Western blots. S6K1 migrated on SDS-PAGE 
as a 70-kD protein.JCB • VOLUME 195 • NUMBER 3 • 2011   438
(Byfield et al., 2005; Nobukuni et al., 2005). Importantly, amino 
acid activation of PLD, as well as hVps34-augmented PLD 
activity, was significantly suppressed by FYVE overexpres-
sion (Fig. 4 B). These observations are consistent with PI3P   
being a key regulator of PLD activity. To gain more direct insight 
into the role of PI3P in regulating PLD1 in cells, we delivered 
PI3P into HEK293 cells using a polyamine carrier (Ozaki et al., 
2000). As shown in Fig. 4 C, exogenous PI3P activated cellular 
PLD1 activity by approximately twofold in the absence of 
amino acids as well as under serum starvation conditions, 
whereas carrier alone or with PI had no effect. Furthermore,   
exogenous PI3P stimulated PLD1 activity equally well in hVps34 
knockdown cells (Fig. 4 D), suggesting that PI3P was sufficient 
for PLD1 activation in the absence of hVps34. Collectively, our 
results strongly suggest that hVps34 activates PLD1 through its 
product PI3P.
hVps34 and then expressed RNAi-resistant recombinant hVps34, 
either wild-type (wt) or kinase-dead. hVps34 knockdown im-
paired amino acid–induced PLD activation, as shown earlier 
(Fig. 2 B), and the expression of recombinant wt-hVps34 res-
cued PLD activation (Fig. 3 C), further validating target speci-
ficity of the hVps34 knockdown. Importantly, expression of the 
kinase-dead  hVps34  did  not  rescue  PLD  activity  from  the 
knockdown (Fig. 3 C), suggesting that activation of PLD1 re-
quires the kinase activity of hVps34.
The requirement of hVps34 kinase activity implies that its 
product, PI3P, may regulate PLD. FYVE domains, when over-
expressed, could sequester cellular PI3P and dominantly inter-
fere with functions of endogenous PI3P-targeting proteins. We 
found that overexpression of an EGFP-2×FYVE fusion protein 
in HEK293 cells dampened S6K1 phosphorylation stimulated by 
amino acids (Fig. 4 A), which is consistent with previous studies 
Figure 2.  hVps34 is necessary for amino acid activation of PLD1 upstream of mTORC1. HEK293 cells were treated as described below, and in vivo PLD 
assays and Western analysis of cell lysates were performed in parallel. (A) Serum-starved cells were subjected to amino acid withdrawal for 2 h and were 
then stimulated with amino acids for 30 min. 10 mM 3-MA and 100 nM rapamycin were added 60 and 30 min before stimulation, respectively, where 
indicated. (B and C) Cells were transduced with lentiviruses expressing two independent shRNAs against hVps34 and a scrambled (scram) sequence as a 
negative control, selected with puromycin, serum starved overnight, and amino acid deprived for 2 h followed by 30 min of amino acid (AA) stimulation (B) 
or insulin (100 nM) stimulation (C). (D) Cells transduced with lentiviruses expressing PLD1-shRNA or scramble control and selected with puromycin were 
transiently transfected with an Myc-hVps34/V5-hVps15 bicistronic construct or empty vector. The cells were then serum starved overnight and amino acid 
deprived for 2 h followed by amino acid stimulation for 30 min. Cell lysates were subjected to Western analysis. (E) Cells were transduced with lentiviruses 
expressing hVps34-shRNA or scramble control, selected with puromycin, serum starved overnight, and then stimulated with 300 µM PA for 30 min. Cell 
lysates were subjected to Western analysis. (F) Cells were treated as in E but amino acid deprived for 2 h followed by amino acid stimulation, PA (300 µM) 
stimulation, or both for 30 min. Predicted molecular masses of the proteins are indicated for Western blots. S6K1 migrated on SDS-PAGE as a 70-kD 
protein. (A–C) All data are mean ± SD or representative blots from three to five independent experiments. A one-sample or paired t test was performed to 
compare the indicated pairs of data. *, P < 0.05; **, P < 0.01.439 PLD mediates amino acid activation of mTORC1 • Yoon et al.
predicted to be required for interaction with phosphoinositide 
lipid anchors based on the published structures of other PX 
domains  and  sequence  alignment  of  known  PX  domains 
(Sato et al., 2001; Du et al., 2003). The PX mutant dis-
played higher basal activity compared with wt PLD1, as pre-
viously reported (Sung et al., 1999), and so did the two point 
mutants (compare the gray bars in Fig. 5 B). Interestingly, 
The PX domain of PLD1 is required for its 
activation by hVps34
The involvement of PI3P in the activation of PLD1 prompted 
us to ask whether this regulation is through the PX domain   
of  PLD1.  We  examined  three  PLD1  mutants:  PX  deleted 
(PX), R118G, and F120A/R179Q (Fig. 5 A). The latter two 
contained point mutations in the PX domain at the residues 
Figure 3.  hVps34 activates PLD1 in cells. (A) HEK293 cells were cotransfected with HA-PLD1 and increasing amounts of bicistronic Myc-hVps34/ 
V5-hVps15 cDNA followed by in vivo PLD assays and Western analysis of cell lysates in parallel samples. (B) Cells were cotransfected with HA-PLD1 and 
Myc-hVps34/V5-hVps15, serum starved overnight, amino acid (AA) deprived for 2 h, and then stimulated with amino acids for 30 min. In vivo PLD assays 
were performed. (C) Cells were transduced with lentiviruses expressing hVps34-shRNA, selected with puromycin, and transfected with wt or kinase-dead 
Myc-hVps34 followed by serum starvation overnight, amino acid deprivation for 2 h, and then stimulation with amino acids for 30 min. In vivo PLD assays 
and Western analysis of cell lysates were performed in parallel. Scram, scrambled. (A–C) All data are mean ± SD or representative blots from three to 
five independent experiments. A one-sample or paired t test was performed to compare the indicated pairs of data. *, P < 0.05; **, P < 0.01. Predicted 
molecular masses of the proteins are indicated for Western blots. S6K1 migrated on SDS-PAGE as a 70-kD protein.
Figure  4.  PI3P  activates  PLD1  in  cells.  
(A)  HEK293  cells  were  cotransfected  with   
HA-S6K1 and GFP-2×FYVE (the latter at two 
different amounts), serum starved overnight, 
amino acid (AA) deprived for 2 h, and then   
stimulated with amino acids for 30 min. Western 
analysis was performed. (B) Cells were trans-
fected with GFP-FYVE at two different amounts 
with or without Myc-hVps34/V5-hVps15 cDNA 
and then treated as in A. In vivo PLD assays 
were  performed.  (C)  Cells  were  transfected 
with  HA-PLD1  followed  by  serum  starvation 
overnight or amino acid withdrawal for 2 h. 
The cells were then stimulated with 15 µM PI3P 
or PI or carrier alone for 30 min. In vivo PLD 
assays were performed. (D) Cells were trans-
duced  with  lentiviruses  expressing  hVps34-
shRNA  or  scramble  (scram),  selected  with 
puromycin, and then transfected with HA-PLD1 
followed  by  serum  starvation  overnight  and 
amino acid withdrawal for 2 h. The cells were 
then  stimulated  with  15  µM  PI3P  or  carrier   
alone in the presence of amino acids for 30 min. 
In vivo PLD assays were performed. (B–D) All 
data are mean ± SD or representative blots   
from three to five independent experiments.   
A one-sample or paired t test was performed 
to  compare  the  indicated  pairs  of  data.   
*, P < 0.05; **, P < 0.01. (A, C, and D) Pre-
dicted molecular masses of the proteins are in-
dicated for Western blots. S6K1 migrated on 
SDS-PAGE as a 70-kD protein.JCB • VOLUME 195 • NUMBER 3 • 2011   440
We also found that hVps34 and PLD1 coimmunoprecip-
itated.  Recombinant  Myc-hVps34  specifically  pulled  down 
endogenous  PLD1,  and,  conversely,  recombinant  FLAG-
PLD1 pulled down endogenous hVps34 (Fig. 5 D). The inter-
action  between  PLD1  and  hVps34  was  not  regulated  by 
amino acid signals, nor was it dependent on the PX domain 
of PLD1 (unpublished data). Although the functional signifi-
cance of this interaction remains uncertain, it is possible that 
the constitutive association of hVps34 and PLD1 offers an 
advantage of proximity in the regulation of PLD1 by hVps34-
produced PI3P.
Amino acids regulate PLD1 translocation 
to the lysosomal area in an hVps34-
dependent fashion
It had been reported that amino acid signals, through the small 
GTPases Rag and the P18–P14–MP1 (Ragulator) complex, 
induce translocation of raptor/mTOR to the late endosomal/
lysosomal region where activation of mTORC1 occurs (Sancak 
et al., 2008, 2010). We wondered whether PLD1, as a key 
regulator of mTORC1 activation, also underwent subcellular 
PI3P did not activate any of these mutants (Fig. 5 B), sug-
gesting that activation of PLD1 by PI3P is dependent on the 
PX domain.
We also examined various PLD1 mutants for their re-
sponse  to  hVps34  overexpression.  In  agreement  with  the 
aforementioned observations, the PX, R118G, and F120A/
R179Q mutants of PLD1 were no longer activated by over-
expression of hVps34 (Fig. 5 C). The Pleckstrin homology (PH) 
domain–deleted PLD1 (PH) lost basal activity, as expected 
from  a  well-established  role  of  PH  domain  in  maintaining 
PLD1 activity (Sung et al., 1999; Hodgkin et al., 2000), and, 
not surprisingly, it was not stimulated by hVps34 overexpres-
sion (Fig. 5 C). A PLD1 mutant with the loop region deleted 
(loop) also displayed higher basal activity, as previously re-
ported (Sung et al., 1999); but, nevertheless, this mutant was 
further activated by hVps34 overexpression (Fig. 5 C). Thus, 
the PX mutations and loop deletion likely resulted in higher 
PLD basal activity via two different mechanisms. The insensi-
tivity of the PX mutants to hVps34 overexpression and exoge-
nous PI3P suggests a specific role of the PX domain in the 
regulation by hVps34 and PI3P.
Figure 5.  The PX domain is required for PLD1 activation by PI3P and hVps34. (A) A schematic representation of the domain structures of PLD1 and its 
mutants used in this study. (B) HEK293 cells were transfected with wt and mutant PLD1 followed by serum starvation overnight and stimulation with 15 µM 
PI3P for 30 min. In vivo PLD assays were performed. Western blots show recombinant PLD1 protein expression. (C) Cells were cotransfected with Myc-
hVps34 and various PLD1 mutants followed by serum starvation overnight and in vivo PLD assays. Western blots show expression of recombinant hVps34 
and various PLD1 proteins. (A–C) All data are mean ± SD from three to five independent experiments. A one-sample or paired t test was performed to 
compare the indicated pairs of data. *, P < 0.05; **, P < 0.01. (D) Cells were transfected with Myc-hVps34 (top) or Flag-PLD1 (bottom). Immunoprecipita-
tion (IP) was performed with anti-Myc or -Flag antibody followed by immunoblotting for recombinant hVps34 and endogenous PLD1 or recombinant PLD1 
and endogenous hVps34, respectively. Predicted molecular masses of proteins are indicated for Western blots.441 PLD mediates amino acid activation of mTORC1 • Yoon et al.
Amino acid–induced PLD1 lysosomal 
translocation is dependent on the  
PX domain and is necessary for  
mTORC1 signaling
We also examined localization of the PLD1 mutants. Compared 
with wt PLD1, which displayed a punctate pattern concentrated at 
the perinuclear region, the PX mutant was dispersed throughout 
the cytoplasm in amino acid–deprived cells, and no change in this 
localization was detected upon amino acid stimulation (Fig. 7,   
A and B). The R118G mutant displayed localization identical to 
that of the PX mutant both in the absence and presence of amino 
acids (Fig. 7, A and B). The loop mutant, on the other hand, trans-
located to the LAMP2-positive region upon amino acid stimulation 
(Fig. 7, A and B). Therefore, amino acid–induced PLD1 trans-
location to the lysosomal region is dependent on its PX domain as 
well as on hVp34 kinase, which is similar to the requirements for 
the catalytic activation of PLD1 by amino acids. Thus, we won-
dered whether catalytic activation of PLD1 might be a prerequi-
site for its translocation. As shown in Fig. S3, the catalytically 
inactive K898R PLD1 mutant (Sung et al., 1997) translocated to 
the LAMP2-positive region in response to amino acid stimula-
tion, suggesting that the catalytic activity of PLD1 is not neces-
sary for its subcellular translocation in response to amino acids.
Collectively,  our  data  clearly  indicate  Vps34-mediated 
amino acid stimulation of PLD1 translocation to the lysosomal 
area. An important question was whether this subcellular trans-
location was functionally relevant to mTORC1 activation. To 
address this issue, it was necessary to separate the activity of 
PLD1  from  its  translocation,  and  the  PX  mutant  of  PLD1 
served that purpose. The activity of PX-PLD1 was comparable 
with wt PLD1 upon amino acid stimulation, even though the 
mutant was insensitive to amino acids (Fig. 7 C), but PX-PLD1 
did not localize to the lysosomal area (Fig. 7, A and B). In com-
plete correlation with their differing abilities to translocate to   
lysosomes, both wt PLD1 and loop-PLD1 enhanced amino 
translocation. PLD1 had been reported to reside on endo-
membranes including Golgi, ER, and late endosomes (Colley   
et al., 1997; Brown et al., 1998; Toda et al., 1999; Freyberg 
et al., 2001). Because an antibody that specifically recog-
nizes endogenous PLD1 by immunostaining was not avail-
able,  we  expressed  recombinant  HA-PLD1  and  examined   
its localization by anti-HA staining. When cells were de-
prived of both serum and amino acids, recombinant PLD1 
was found in cytoplasmic puncta concentrated in the peri-
nuclear  region  (Fig.  6  A),  whereas  mTOR  was  in  puncta   
distributed throughout the cytoplasm (Fig. 6 B). Upon acute   
(30 min) stimulation by amino acids, some of the mTOR pro-
tein translocated to the lysosomal region marked by LAMP2 
(Fig. 6 B), which is consistent with previous studies (Sancak 
et al., 2008, 2010; Flinn et al., 2010). Importantly, transloca-
tion of PLD1 to the LAMP2-positive lysosomal region upon 
amino acid stimulation was also clearly evident (Fig. 6 A). 
Quantification  of  the  imaging  results  showed  that  76  and 
78% of PLD1- and mTOR-staining cells, respectively, dis-
played this localization pattern upon amino acid stimulation 
(Fig.  6  D).  As  expected  from  their  translocation  into  the 
LAMP2-positive region, mTOR and PLD1 signals overlapped 
upon amino acid stimulation (Fig. 6 C). Recombinant HA-PLD2 
was found predominantly at the periphery of the cell, as pre-
viously reported (Du et al., 2004), and amino acid stimula-
tion had no effect on PLD2 localization (Fig. S2).
Interestingly, the amino acid–induced PLD1 transloca-
tion was abolished when hVps34 was knocked down or when 
the cells were treated with 3-MA (Fig. 6, A and D), suggesting 
that hVps34 is necessary to transduce amino acid signals to 
effect  PLD1  translocation  to  the  lysosomal  region.  mTOR 
translocation, on the other hand, was not affected by hVps34 
knockdown or 3-MA treatment (Fig. 6, B and D). As expected, 
3-MA treatment or hVps34 knockdown abolished amino acid–
induced colocalization of mTOR and PLD1 (Fig. 6 C).
Figure 6.  Amino acids regulate PLD1 translocation to the lysosomal region in an hVps34-dependent fashion. (A) HEK293 cells were transfected with 
HA-PLD1 followed by serum starvation overnight and amino acid (AA) deprivation for 2 h. Some cells were transduced with lentiviruses expressing hVps34-
shRNA (hVps34 knockdown [KD]) and selected with puromycin before transfection of HA-PLD1, whereas others were treated with 10 mM 3-MA for 1 h 
before amino acid stimulation. Upon amino acid stimulation for 30 min, cells were fixed and immunostained with anti-HA and -LAMP2 antibodies. (B) Cells 
were treated as in A without transfection and immunostained with anti-mTOR and -LAMP2 antibodies. (C) Cells were transfected with HA-PLD1, treated as 
in A, and then immunostained with anti-HA and -mTOR antibodies. (A–C) The merged images were pseudocolored as follows: LAMP2 in red and PLD1 
and mTOR in green (A and B) and PLD1 in red and mTOR in green (C). Enlarged images of the merges are shown in the rightmost columns. Bars, 5 µm; 
(enlarged images) 0.5 µm. (D) Percentage of LAMP2-colocalized cells among HA- (for PLD1) or mTOR-positive cells was quantified for experiments shown 
in A and B. Cells with the majority of HA-PLD1 or mTOR signals overlapping with LAMP2 signals were scored as colocalizing. Mean results of three inde-
pendent experiments are shown with error bars representing SD.JCB • VOLUME 195 • NUMBER 3 • 2011   442
overexpression did not have a significant effect (Fig. 8 B). Hence, 
hVps34 and the PX domain of PLD1 are important for cell size 
control, consistent with their roles in regulating mTORC1.
PLD1 and Rag pathways act in parallel to 
mediate amino acid activation of mTORC1
As both PLD1 and mTORC1 undergo amino acid–stimulated 
translocation  to  the  lysosomal  area,  an  obvious  question  is 
whether the two pathways intersect. We had already found that 
hVps34 regulates PLD1 translocation without affecting mTOR 
translocation (Fig. 6), and we wished to address whether Rag 
and the P18–P14–MP1 Ragulator complex, responsible for 
mTORC1 lysosomal translocation (Sancak et al., 2008, 2010), 
are involved in the regulation of PLD1. To that end, we exam-
ined the effects of knocking down Rag and P18 on PLD1 acti-
vation and translocation. Four Rag proteins (Rag A, B, C, and D) 
function  as  heterodimers  to  regulate  mTORC1  translocation 
(Sancak et al., 2008). We knocked down Rag C and Rag D si-
multaneously to eliminate all Rag function. As shown in Fig. 9 A, 
knockdown of Rag, P18, raptor, and hVps34 each drastically 
blocked amino acid activation of S6K1, suggesting that each of 
these regulators is essential for mTORC1 signaling. But knock-
down of Rag, P18, and raptor did not affect amino acid activa-
tion of PLD (Fig. 9 B) or PLD1 lysosomal translocation (Fig. 9 C). 
Therefore, the hVps34-PLD1 pathway is activated by amino 
acid signals independently of the Rag pathway.
acid–stimulated  S6K1  phosphorylation,  whereas  PX-PLD1 
did not have this effect (Fig. 7 D). Although the loop mutant 
displayed higher PLD activity than the wt protein, it activated 
S6K1 to a similar degree as the wt, possibly because maximal 
S6K1 activation in the absence of mitogens was already reached. 
These observations strongly suggest that the catalytic activity of 
PLD1 alone is insufficient for mTORC1 activation and that the 
translocation of PLD1 is necessary for this activation.
Further validating the importance of PLD1 lysosomal trans-
location is our observation that exogenous PI3P did not induce 
PLD1 translocation (Fig. S4 A) or S6K1 activation (Fig. S4 B), 
even though it activated PLD1 to a similar extent as amino acid 
stimulation (Fig. S4 C). PI3P binding to the PX domain of PLD1 
appears to be required for both the catalytic activation and trans-
location of PLD1, but, although this interaction may be suffi-
cient for the activation of PLD1, translocation of PLD1 most 
likely has additional requirements yet to be identified.
hVps34 and PLD1 control cell size
To assess the biological significance of the mechanistic connec-
tion  between  hVps34,  PLD1,  and  mTORC1,  we  considered   
cell size regulation, a prominent function of mTORC1. Indeed, 
knockdown of hVps34 and PLD1 each reduced cell size by 
8%, similar to the effects of raptor knockdown and rapa-
mycin treatment (Fig. 8 A). On the other hand, overexpression 
of wt PLD1 increased cell size by 6%, whereas PX-PLD1 
Figure 7.  PX domain is necessary for amino acid–induced PLD1 lysosomal translocation and mTORC1 signaling. (A) HEK293 cells were transfected with 
various mutants of HA-PLD1 followed by serum starvation overnight and amino acid (AA) deprivation for 2 h. Upon amino acid stimulation for 30 min, 
cells were fixed and immunostained with anti-HA and -LAMP2 antibodies. Images were processed as described in Fig. 5. Bars, 5 µm; (enlarged images) 
0.5 µm. (B) Percentage of LAMP2-colocalized cells among HA-PLD–positive cells was quantified for experiments shown in A, as described in Fig. 6 D.   
(C) Cells were transfected with wt-, PX-, or loop-PLD1, serum and amino acid starved, and then stimulated with amino acids for 30 min followed by in vivo 
PLD assays. (D) Cells were cotransfected with Myc-S6K1 and wt-, PX-, or loop-PLD1, treated as in C, and subjected to Western analysis. Quantification 
of Western band intensities was performed by densitometry of x-ray film images using ImageJ software (National Institutes of Health). The levels of pS6K1 
relative to total S6K1 are shown. Predicted molecular masses of the proteins are indicated for Western blots. S6K1 migrated on SDS-PAGE as a 70-kD 
protein. (B–D) Three independent experiments are shown with error bars representing SD. *, P < 0.05; **, P < 0.01.443 PLD mediates amino acid activation of mTORC1 • Yoon et al.
mTOR  translocation  to  the  same  subcellular  locus  (Sancak   
et al., 2008, 2010; Flinn et al., 2010), suggests a unifying mech-
anism of spatial regulation underlying mTORC1 activation by 
amino acids (Fig. 10).
Amino acid regulation of PLD1
The finding of PLD1 activation by amino acids adds a new class 
of signals to the list of stimuli known to activate PLD1 (Frohman 
et al., 1999). During the preparation of this manuscript, Xu et al. 
(2011) reported similar effects of nutrients on PLD activity, 
corroborating our findings. The modest (nevertheless signifi-
cant) degree of PLD1 activation by amino acids is comparable 
with those stimulated by other known PLD agonists such as   
serum and insulin and therefore is likely to be functionally sig-
nificant. It should also be kept in mind that PLD1 is involved   
in many cellular functions/pathways, only a fraction of which 
may  participate  in  amino  acid/mTORC1  regulation.  Indeed, 
amino acids induce lysosomal translocation of a subpool of 
PLD1, similar to mTOR. This translocation may synergize with 
the enzymatic activation of PLD1, resulting in a functionally 
significant response to amino acids. It is unclear why the effect 
of amino acids is specific for PLD1, even though the PX do-
main of PLD2 shares very high sequence similarity with that of 
PLD1. Differential subcellular localization of the two PLDs 
may be responsible for their distinct behaviors upon amino acid 
stimulation. Indeed, recombinant PLD2 is localized predomi-
nantly to the cell periphery (Du et al., 2004), whereas both 
PLD1 and hVps34 are distributed in the cytoplasm and through-
out the endosomal system (Figs. 6 and S2; Brown et al., 1998; 
Toda et al., 1999; Freyberg et al., 2001; Kihara et al., 2001;   
Itakura et al., 2008). We note that in HEK293 cells, there is little 
endogenous PLD2 protein, and our observation of amino acid 
insensitivity was solely based on recombinant PLD2. Thus, a 
role for PLD2 in amino acid–sensing mTORC1 signaling is still 
Sancak et al. (2008) reported that expression of a consti-
tutively active Rag complex activated mTORC1 in the absence 
of amino acids. We confirmed this observation with coexpres-
sion of Rag mutants that represented Rag B–GTP (Q99L) and 
Rag C–GDP (S75L), which stimulated S6K1 activation in cells 
deprived of both serum and amino acids (compare first and fifth 
lanes  in  Fig.  9  D).  However,  amino  acids  further  enhanced 
S6K1 activation in cells expressing constitutively active Rag. 
Importantly, PLD1 knockdown impaired S6K1 activation in-
duced by Rag both in the presence and absence of amino acids 
(Fig. 9 D). This observation suggests that the ability of consti-
tutively active Rag to activate mTORC1 is most likely depen-
dent on the basal activity of PLD1, which is present in the 
lysosomal region in a portion of the cells without amino acid 
stimulation (Fig. 6 D). Collectively, our data support a model in 
which the hVps34-PLD1 and Rag pathways act in parallel—
both necessary—to activate mTORC1.
Discussion
Although several mechanisms have been described for the acti-
vation of the mTORC1 signaling network by amino acids in re-
cent years, gaps have remained in this intricate circuitry. Our 
present study has revealed a new role of PLD1 in transducing 
amino acid signals upstream of mTORC1 and filled a gap be-
tween hVps34 and mTORC1 in the amino acid–sensing path-
way. A direct regulatory relationship is established for hVps34 
and PLD1, in that hVps34 activates PLD1 catalytic activity and 
induces its subcellular translocation through a functional inter-
action between PI3P and the PX domain in PLD1. With its pre-
viously  established  role  in  mitogenic  signaling,  PLD1  now 
emerges as an integrator of amino acid and mitogen signals up-
stream of mTORC1. Furthermore, PLD1 translocation to the 
lysosomal region upon amino acid stimulation, simultaneous to 
Figure 8.  hVps34 and PLD1 regulate cell size. 
(A) HEK293 cells were transduced with lenti-
viruses expressing shRNAs for raptor, hVps34, 
or  PLD1,  puromycin  selected,  and  then  sub-
jected  to  cell  size  measurement  of  median 
forward scatter-height. The result of overnight 
treatment with 100 nM rapamycin is included   
as a control. Representative histograms are 
also shown, with cell counts in arbitrary units. 
(B) Cells were transfected with wt- or PX-PLD1 
together in pCDNA3 (vector), selected with 
G418 for 3 d, and then subjected to cell size 
measurement as described in A. A one-sample   
t test was performed to compare each data with 
the control. Three independent experiments were 
performed, and the results of mean ± SD are 
shown in the graphs. *, P < 0.05; **, P < 0.01.JCB • VOLUME 195 • NUMBER 3 • 2011   444
early endosomes (Gillooly et al., 2000). However, lower con-
centrations of PI3P in other subcellular locations could still be 
physiologically significant. In fact, hVps34 has been found on 
late endosomes (Stein et al., 2003; Cao et al., 2007) and is 
known to regulate multivesicular body generation (Futter et al., 
2001). Furthermore, a knockdown study has revealed a specific 
function of hVps34 in the late endosomes in human U-251 glio-
blastoma cells (Johnson et al., 2006). Our present study iden-
tifies PLD1 as a new effector for hVps34-produced PI3P. 
Although we do not know where exactly the interaction between 
PLD1 and hVps34/PI3P occurs in the cell, it is clear that PLD1 
translocation to the late endosomal/lysosomal surface upon amino 
acid stimulation is dependent on hVps34. However, hVps34   
possible in cells in which PLD2 is the predominant PLD iso-
form. The involvement of PLD2 in mTORC1 signaling has 
been reported by others (Chen et al., 2005; Ha et al., 2006;   
Toschi et al., 2009).
A new effector for hVps34
Among the various cellular functions regulated by hVps34, two 
major ones are vesicular trafficking and autophagy, involving 
distinct complexes containing hVps34 (Backer, 2008). Regula-
tion of amino acid–sensing mTOR signaling may be mediated 
by yet another population of hVps34, although there may exist 
an interrelationship among these pools of hVps34. PI3P, pre-
sumably mediating all hVps34 functions, is found enriched on 
Figure 9.  PLD1 and Rag pathways act in parallel to mediate amino acid activation of mTORC1. (A) HEK293 cells were transduced with lentiviruses 
expressing shRNAs, selected with puromycin, serum starved, and amino acid (AA) deprived followed by amino acid stimulation for 30 min. Cell lysates 
were analyzed by Western blotting. scram, scrambled. (B) Cells were treated as in A, and in vivo PLD assays were performed. *, P < 0.05; **, P < 0.01.   
(C, left) Cells were transduced by lentiviruses expressing shRNAs, selected with puromycin, and then transfected with HA-PLD1 followed by serum starvation 
and amino acid deprivation. Upon amino acid stimulation for 30 min, cells were fixed and immunostained with anti-HA or -mTOR together with anti-LAMP2 
antibodies. The merged images were pseudocolored as follows: LAMP2 in red and PLD1 and mTOR in green. Bars, 5 µm; (enlarged images) 0.5 µm.   
(right) Percentage of LAMP2-colocalized cells among HA- or mTOR-positive cells was quantified for three independent experiments as described in Fig. 6 D, 
and the results of mean ± SD are shown in the graph. (D) Cells were transduced with lentiviruses expressing shRNAs, selected with puromycin, and then 
transfected with Rag B/C. Upon serum starvation and amino acid deprivation followed by amino acid stimulation for 30 min, cells were lysed for Western 
analysis. Predicted molecular masses of the proteins are indicated for Western blots. S6K1 migrated on SDS-PAGE as a 70-kD protein.445 PLD mediates amino acid activation of mTORC1 • Yoon et al.
amino acids–hVps34-PLD1 pathway. It has been reported that 
overexpression of a constitutively active Rag dimer or recombi-
nant raptor fused to the membrane-targeting signal of Rheb can 
override the requirement of amino acid signals for mTORC1   
activation (Sancak et al., 2008, 2010), suggesting that the Rag 
pathway may be sufficient to mediate amino acid activation of 
mTORC1. However, we have found that amino acids further   
activate S6K1 in cells overexpressing active Rag and that PLD1 
is necessary for Rag activation of S6K1 (Fig. 9 D), validating the 
requirement  of  two  parallel  pathways  for  the  activation  of 
mTORC1 (Fig. 10). In conclusion, the collective evidence we 
have presented identifies a critical role of the hVps34-PLD1 
pathway in amino acid activation of mTORC1 signaling and   
unveils a clearer view of this nutrient-sensing network of   
central importance.
Materials and methods
Antibodies and other reagents
The antibodies used were obtained from the following sources: anti-FLAG 
M2  and  anti-P18  from  Sigma-Aldrich;  anti-Myc  (9E10.2)  and  anti-HA 
(16B12) from Covance; anti-tubulin and anti-LAMP2 from Abcam; anti-V5 
from Invitrogen; and all other antibodies from Cell Signaling Technology. 
PLD1 antibody was generated by Proteintech Group, Inc. using a synthetic 
peptide corresponding to the C-terminal sequence of PLD1. Rapamycin 
was purchased from LC Laboratories. 9,10-
3H-oleic acid was obtained 
from PerkinElmer. PI3P and its polyamine carrier (no. 3) were obtained 
from Echelon Biosciences Inc. 1,2-dioctanoyl-sn-glycero-3–PA (C8-PA) was 
obtained from Avanti Polar Lipids, Inc. All other reagents were obtained 
from Sigma-Aldrich.
Plasmids
The following plasmids have been previously reported: Myc-S6K1, HA-S6K1, 
and HA-PLD1 (Fang et al., 2003); wt and kinase-dead (D743I and N748I) 
Myc-hVps34 (Row et al., 2001; Byfield et al., 2005); bicistronic hVps34/
hVps15 (Yan et al., 2009); all PLD1 mutants (Sung et al., 1999; Du et al., 
2003); and HA-PLD2 (Colley et al., 1997). HA-GST-RagB-Q99L and   
HA-GST–Rag C–S75L were obtained from Addgene (Sancak et al., 2008). 
The RNAi-resistant mutants of wt and kinase-dead hVps34 were created   
by standard site mutagenesis methods, changing nucleotides 2,436–2,438 
from 5-TATTCT-3 to 5-TACTCC-3. The EGFP-2×FYVE construct was a 
gift from the Stenmark laboratory at the Norwegian Radium Hospital 
(Gillooly et al., 2000).
Cell culture and transfection
HEK293 cells were grown in DME containing 10% FBS at 37°C with 5% 
CO2. Transient transfections were performed with PolyFect (QIAGEN) fol-
lowing the manufacturer’s recommendations. Serum starvation was per-
formed  by  incubating  cells  in  serum-free  DME  at  37°C  with  5%  CO2 
overnight. Amino acid or Leu starvation was achieved by incubation in 
amino acid– or Leu-free DME (HyClone) for 2 h after serum starvation, re-
spectively. Amino acid or Leu stimulation was performed by incubating 
cells in regular DME for 30 min. Detailed conditions for serum, insulin, and 
PA  stimulation  are  described  in  the  figure  Legends  where  applicable.   
C8-PA vesicles were freshly made for each experiment as previously de-
scribed (Yoon et al., 2011). In brief, C8-PA in chloroform was dried and 
then resuspended in 250 µl Dulbecco’s PBS to a concentration of 6 mM 
itself appears to be distributed throughout the cytoplasm and 
the endosomal system without detectable translocation in re-
sponse to amino acids (unpublished data). Recently, Dall’Armi 
et al. (2010) reported localization of PLD1 to autophagosomes 
upon nutrient deprivation, which also appeared to be dependent 
on hVps34.
Although the PX domain of PLD is highly homologous to 
those that have been shown to bind phosphoinositides, previous 
characterization of the PLD1 PX domain has not led to a clear con-
sensus regarding its lipid-binding property and function (Morris, 
2007). Depending on the methods used to assess lipid binding, 
PLD1 PX has been shown to preferentially bind either PI-3,4,5-P3 
(Stahelin et al., 2004; Lee et al., 2005) or PI5P in vitro (Du et al., 
2003). Although not of the highest affinity, PI3P has also been 
shown to bind the PX domain of PLD1 and activate PLD1 in vitro 
(Hodgkin et al., 2000; Stahelin et al., 2004). It is conceivable that 
an intrinsically low affinity between PI3P and PLD could be over-
come by a high local concentration of the lipid in the cells, such 
as when exogenous PI3P was delivered into the cells or when 
the cells were stimulated by amino acids. The physical interaction 
between PLD1 and hVps34 may confer proximity advantage and 
increase the local concentration of PI3P for effective binding and 
subsequent activation and translocation of PLD1.
Two pathways converging to activate 
mTORC1 at the late endosomes/lysosomes
It has been shown that amino acids stimulate mTORC1 trans-
location to the lysosomal region where Rheb presumably resides, 
and this translocation is mediated by Rag and the P18–P14–MP1 
Ragulator  complex  (Sancak  et  al.,  2008,  2010).  Our  present 
study suggests that PLD1 translocation in response to the same 
signal, through hVps34 and PI3P, occurs independently and in 
parallel to Rag-mediated mTORC1 translocation (Fig. 10). The 
translocation of PLD1 to this distinct location of mTORC1 acti-
vation further validates the key role of this protein in mediating 
both mitogenic and amino acid signals to mTORC1 signaling.
Consistent  with  the  model  of  two  independent  amino 
acid–sensing pathways working in parallel (Fig. 10), neither 
hVps34 overexpression (Flinn et al., 2010) nor hVps34 knock-
down (Fig. 6 B) affects mTORC1 translocation. Conversely, 
knockdown of Rag, P18, or raptor has no effect on PLD1 activa-
tion or translocation (Fig. 9). The fact that PA alone is not suffi-
cient to activate mTORC1 signaling in the absence of amino 
acids (Fang et al., 2001) can be readily explained by the parallel 
requirement of mTORC1 translocation via Rag. On the other 
hand, PA rescues amino acid activation of mTORC1 from the 
negative effect of hVps34 knockdown, in full agreement with an 
Figure 10.  A proposed model for amino acid–sensing mTORC1 
signaling. Upon amino acid stimulation, two parallel pathways 
converge on the lysosome to activate mTORC1.JCB • VOLUME 195 • NUMBER 3 • 2011   446
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